文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂的使用与急性肾损伤后结局的相关性

Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With Outcomes After Acute Kidney Injury.
PubMed 文献 · JAMA Intern Med · 2018-01-01
一句话结论急性肾损伤出院后使用ACEI或ARB似乎与2年死亡率降低相关,但肾脏原因住院风险升高,需谨慎监测肾脏并发症。

这项回顾性队列研究基于加拿大阿尔伯塔肾脏疾病网络数据库,纳入2008年7月1日至2015年3月31日期间住院发生急性肾损伤且存活出院的46253名成人,随访至少2年。出院后6个月内48.0%的患者被处方ACEI或ARB。经倾向性评分匹配及多因素调整后,ACEI或ARB使用与2年死亡率降低相关(调整后HR 0.85,95%CI 0.81-0.89),但与肾脏原因住院风险升高相关(调整后HR 1.28,95%CI 1.12-1.46),与进展至终末期肾病无关联。作者认为急性肾损伤后使用ACEI或ARB可能存在获益,但可能需要谨慎监测肾脏特异性并发症。

要点

  • 急性肾损伤存活出院患者中,出院后6个月内使用ACEI或ARB与2年死亡率降低相关(调整后HR 0.85,95%CI 0.81-0.89)。
  • 使用ACEI或ARB的患者肾脏原因住院风险更高(调整后HR 1.28,95%CI 1.12-1.46)。
  • ACEI或ARB使用与进展至终末期肾病无关联。
  • 作者认为急性肾损伤后使用ACEI或ARB可能存在获益,但可能需要谨慎监测肾脏特异性并发症。
  • 该研究为回顾性队列研究,结果需谨慎解读。

适用人群与场景

  • 18岁及以上、住院期间发生急性肾损伤且存活出院的成人,数据来自加拿大阿尔伯塔肾脏疾病网络人群数据库。
  • 急性肾损伤定义为住院前与住院期间峰值血清肌酐浓度之间升高50%。

诊断标准与关键阈值

  • 急性肾损伤定义:住院前与住院期间峰值血清肌酐浓度之间升高50%。

研究设计与关键结果

  • 研究类型:回顾性队列研究;样本量:46253名成人;人群:加拿大阿尔伯塔省2008年7月1日至2015年3月31日住院发生急性肾损伤且存活出院者,随访至少2年。
  • 暴露:出院后6个月内使用ACEI或ARB;46253名参与者中22193名(48.0%)在出院后6个月内被处方ACEI或ARB。
  • 主要终点:死亡;经调整后,ACEI或ARB使用与2年死亡率降低相关(调整后HR 0.85,95%CI 0.81-0.89)。
  • 次要终点:肾脏原因住院风险升高(调整后HR 1.28,95%CI 1.12-1.46);与进展至终末期肾病无关联。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为急性肾损伤后使用ACEI或ARB可能存在获益,但可能需要谨慎监测肾脏特异性并发症。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Patients with acute kidney injury (AKI) are at an increased long-term risk of death. Effective strategies that improve long-term outcomes in patients with AKI are unknown.

OBJECTIVE: To evaluate whether the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) after hospital discharge is associated with better outcomes in patients with AKI.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used data from the Alberta Kidney Disease Network population database to evaluate 46 253 adults 18 years or older with an episode of AKI during a hospitalization between July 1, 2008, and March 31, 2015, in Alberta, Canada. All patients who survived to hospital discharge were followed up for a minimum of 2 years.

EXPOSURES: Use of an ACEI or ARB within 6 months after hospital discharge.

MAIN OUTCOMES AND MEASURES: The primary outcome was mortality; secondary outcomes included hospitalization for a renal cause, end-stage renal disease (ESRD), and a composite outcome of ESRD or sustained doubling of serum creatinine concentration. An AKI was defined as a 50% increase between prehospital and peak in-hospital serum creatinine concentrations. Propensity scores were used to construct a matched-pairs cohort of patients who did and did not have a prescription for an ACEI or ARB within 6 months after hospital discharge.

RESULTS: The study evaluated 46 253 adults (mean [SD] age, 68.6 [16.4] years; 24 436 [52.8%] male). Within 6 months of discharge, 22 193 (48.0%) of the participants were prescribed an ACEI or ARB. After adjustment for comorbidities, ACEI or ARB use before admission, demographics, baseline kidney function, other factors related to index hospitalization, and prior health care services, ACEI or ARB use was associated with lower mortality in patients with AKI after 2 years (adjusted hazard ratio, 0.85; 95% CI, 0.81-0.89). However, patients who received an ACEI or ARB had a higher risk of hospitalization for a renal cause (adjusted hazard ratio, 1.28; 95% CI, 1.12-1.46). No association was found between ACEI or ARB use and progression to ESRD.

CONCLUSIONS AND RELEVANCE: Among patients with AKI, ACEI or ARB therapy appeared to be associated with lower mortality but a higher risk of hospitalization for a renal cause. These results suggest a potential benefit of ACEI or ARB use after AKI, but cautious monitoring for renal-specific complications may be warranted.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Brar S, Ye F, James MT, et al. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With Outcomes After Acute Kidney Injury. JAMA Intern Med. 2018. PMID: 30422153. doi:10.1001/jamainternmed.2018.4749

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。